Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AnnexonANNX +2.94%34 Quick Ratio is 6.35 as of Mar. 2026, which is 43% below its 10-year median of 11.10. GuruFocus rates ANNX with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Annexon ranks better than 66.34% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Annexon's quick ratio for the quarter that ended in Mar. 2026 was 6.35.
Annexon has a quick ratio of 6.35. It generally indicates good short-term financial strength.
The historical rank and industry rank for Annexon's Quick Ratio or its related term are showing as below:
ANNX'
s Quick Ratio Range Over the Past 10 Years
Min: 4.42 Med: 11.1 Max: 41.56
Current: 6.35
During the past 8 years, Annexon's highest Quick Ratio was 41.56. The lowest was 4.42. And the median was 11.10.
ANNX's Quick Ratio is ranked better than 66.34% of 1411
companies
in the Biotechnology industry
Industry Median: 3.56
vs ANNX: 6.35
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Annexon Quick Ratio Related Terms
Annexon Quick Ratio Historical Data
* Premium members only.
The historical data trend for Annexon's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Annexon's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annexon Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annexon's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Annexon's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Annexon's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annexon (ANNX) has a Quick Ratio of 6.35 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Annexon and its competitors. This is 43% below median its historical median of 11.10. Over the past decade, Annexon's Quick Ratio has ranged from 4.42 to 41.56. According to the industry distribution chart, Annexon ranks #475 out of 1411 companies in the Biotechnology industry, placing it in the top 33.7%.
Is Annexon's Quick Ratio too high?
Annexon's current Quick Ratio of 6.35 is 43% below median its 10-year median of 11.10. Over the past 10 years, this metric has ranged from a low of 4.42 to a high of 41.56. The Biotechnology industry median Quick Ratio is 3.56. Annexon's value of 6.35 is 78.4% above this industry median. Based on the distribution chart, Annexon ranks #475 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Annexon has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Annexon's Quick Ratio compare to ABUS and TBPH?
According to the Biotechnology industry distribution chart, Annexon ranks #475 out of 1411 companies for Quick Ratio. This puts Annexon in the upper half of its industry. The industry median Quick Ratio is 3.56. Annexon's value of 6.35 is 78.4% above this benchmark. Historically, Annexon's own Quick Ratio has ranged from 4.42 to 41.56 over the past decade. While the company's 10-year median is 11.10 vs. the industry median of 3.56, Annexon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.56, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annexon's current Quick Ratio of 6.35 is 78.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Annexon and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annexon's current Quick Ratio is 6.35, which is 43% below median its own 10-year median of 11.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexon stock overvalued right now?
Annexon (ANNX) has a current Quick Ratio of 6.35. The current Quick Ratio is 6.35, which is 43% below median its 10-year median of 11.10 and 78.4% above the Biotechnology industry median of 3.56. Annexon's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Annexon (ANNX), the current Quick Ratio is 6.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
34GF Score
Get the complete analysis for ANNX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANNX has been successfully added to your 
